Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-03-04

FDA Approved: ZUBSOLV — Supplemental Application (Orexo US, Inc.)

View source ↗

Summary

FDA approved a supplemental application for ZUBSOLV (buprenorphine/naloxone) from Orexo US, Inc. The approval covers changes to labeling and/or approved indicat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ZUBSOLV (Buprenorphine hydrochloride and naloxone hydrochloride)

Snippet

SUPPL AP for ZUBSOLV (BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE)